SAN DIEGO, June 27, 2016 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, announced today that the Supreme Court of the United States denied its petition to
review decisions by lower Federal courts that the claims of
Sequenom's U.S. Patent No. 6,258,540 ("'540 Patent") are not patent
eligible under the patent eligibility criteria established by the
Supreme Court's Mayo Collaborative Services v. Prometheus
Laboratories decision. In the petition, Sequenom urged the
Court to hear the case because the Court is uniquely suited to
reconcile and interpret the patent eligibility criteria established
in its Mayo decision. Sequenom will pursue no
further appeal opportunities for review of the '540 Patent.
![SEQUENOM logo. SEQUENOM logo.](http://photos.prnewswire.com/prnvar/20160225/337675LOGO)
"We are disappointed that the Supreme Court denied our petition
and will not review the patent eligibility of the groundbreaking
techniques embodied in the '540 Patent," said Dirk van den Boom, Ph.D., President and CEO of
Sequenom. "We believe that the Supreme Court missed an ideal
opportunity to clarify patent eligibility criteria not only to
protect the significant investments made by Sequenom but also by
other innovative organizations to advance the standard of patient
care and treatment. We fear this decision will discourage
such investments in the future."
As previously stated, as a practical matter, Sequenom believes
that the ruling has little business impact as it has been operating
under the District Court's invalidity ruling since October, 2013
and due to the pooling arrangement of NIPT intellectual property
entered into with Illumina, Inc. in December, 2014. In
addition, valid and enforceable patents with claims equivalent to
those of the '540 Patent are issued
in Europe, Japan, Hong Kong, Canada and
Australia.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and services.
The Company serves patients and physicians by providing early
patient management information. To learn how Sequenom is
interpreting the genome to improve your life, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, HerediT®
UNIVERSAL, MaterniT® GENOME, MaterniT® 21
PLUS, NextView®, SensiGene® and
VisibiliT™, these molecular genetic laboratory-developed
tests provide early patient management information for
obstetricians, geneticists, and maternal fetal medicine
specialists. Sequenom Laboratories is changing the landscape in
genetic diagnostics using proprietary cutting edge technologies.
Visit www.laboratories.sequenom.com and follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services and the expected impact of the
Court's decision. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking
statements. Risks are described more fully in the
Company's filings with the Securities and Exchange Commission,
including without limitation the Company's most recent Annual
Report on Form 10-K and other documents subsequently filed with or
furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Logo -
http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/the-supreme-court-of-the-united-states-denies-sequenoms-petition-requesting-review-of-decision-on-540-patent-300290519.html
SOURCE Sequenom, Inc.